LBRX
Income statement / Annual
Last year (2024), LB Pharmaceuticals Inc Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, LB Pharmaceuticals Inc Common Stock's net income was -$63.10 M.
See LB Pharmaceuticals Inc Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$51.17 M
|
$7.85 M
|
$1.35 M
|
| General & Administrative Expenses |
$13.66 M
|
$3.53 M
|
$1.46 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.66 M
|
$3.53 M
|
$1.46 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$64.83 M
|
$11.38 M
|
$2.81 M
|
| Cost And Expenses |
$64.83 M
|
$11.38 M
|
$2.81 M
|
| Interest Income |
$1.72 M
|
$811.00 K
|
$73.00 K
|
| Interest Expense |
$0.00
|
$4.83 M
|
$2.15 M
|
| Depreciation & Amortization |
$91.00 K
|
$4.00 K
|
$2.00 K
|
| EBITDA |
-$63.01 M |
-$1.45 M |
-$12.19 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.73 M
|
$5.10 M
|
-$11.54 M
|
| Income Before Tax |
-$63.10 M
|
-$6.27 M
|
-$14.35 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$1.00 K
|
$1.00 K
|
$1.00 K
|
| Net Income |
-$63.10 M
|
-$6.28 M
|
-$14.35 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-17.83 |
-1.77 |
-4.05 |
| EPS Diluted |
-17.83 |
-1.77 |
-4.05 |
| Weighted Average Shares Out |
$3.54 M
|
$3.54 M
|
$3.54 M
|
| Weighted Average Shares Out Diluted |
$3.54 M
|
$3.54 M
|
$3.54 M
|
| Link |
|
|
|
